|
HUE036780T2
(hu)
|
2008-04-09 |
2018-07-30 |
Genentech Inc |
Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére
|
|
MA40835A
(fr)
|
2014-10-23 |
2017-08-29 |
Biogen Ma Inc |
Anticorps anti-gpiib/iiia et leurs utilisations
|
|
MA40861A
(fr)
*
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Anticorps anti-glycoprotéines iib/iiia
|
|
EP3458485B1
(en)
|
2016-05-19 |
2021-12-29 |
The General Hospital Corporation |
Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
|
|
CA3044664C
(en)
|
2016-11-30 |
2022-11-22 |
Oncomed Pharmaceuticals, Inc. |
Methods for treatment of cancer comprising tigit-binding agents
|
|
US11021537B2
(en)
|
2017-05-01 |
2021-06-01 |
Agenus Inc. |
Anti-TIGIT antibodies and methods of use thereof
|
|
IL272227B2
(en)
*
|
2017-07-27 |
2025-09-01 |
iTeos Belgium SA |
Anti-tigit antibodies
|
|
TW202023625A
(zh)
|
2018-08-23 |
2020-07-01 |
美商西雅圖遺傳學公司 |
抗tigit抗體
|
|
US11376255B2
(en)
|
2018-09-11 |
2022-07-05 |
iTeos Belgium SA |
Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
|
|
CN113226324B
(zh)
|
2018-09-11 |
2024-12-31 |
Iteos比利时公司 |
作为a2a抑制剂的硫代氨基甲酸酯衍生物、其药物组合物以及与抗癌剂的组合
|
|
EP3898677A1
(en)
|
2018-12-21 |
2021-10-27 |
OSE Immunotherapeutics |
Bifunctional anti-pd-1/il-7 molecule
|
|
WO2020165374A1
(en)
|
2019-02-14 |
2020-08-20 |
Ose Immunotherapeutics |
Bifunctional molecule comprising il-15ra
|
|
US20200318200A1
(en)
|
2019-04-02 |
2020-10-08 |
The Brigham And Women's Hospital, Inc. |
Methods for Identifying Progression of a Primary Melanoma
|
|
AU2020290916A1
(en)
*
|
2019-06-13 |
2021-11-04 |
Green Cross Corporation |
Antibody to TIGIT and use thereof
|
|
CN114729040A
(zh)
*
|
2019-06-21 |
2022-07-08 |
单细胞技术股份有限公司 |
抗tigit抗体
|
|
IL292757A
(en)
*
|
2019-11-05 |
2022-07-01 |
Merck Patent Gmbh |
Anti-tigit antibodies and uses thereof
|
|
WO2021122866A1
(en)
|
2019-12-17 |
2021-06-24 |
Ose Immunotherapeutics |
Bifunctional molecules comprising an il-7 variant
|
|
CN112409450B
(zh)
*
|
2020-03-29 |
2023-01-24 |
郑州大学 |
TIGIT-IgV的亲和剂及其应用
|
|
CN113563470B
(zh)
*
|
2020-04-29 |
2023-02-10 |
广州昂科免疫生物技术有限公司 |
结合tigit抗原的抗体及其制备方法与应用
|
|
EP4147053B1
(en)
|
2020-05-07 |
2026-01-28 |
Institut Curie |
Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
|
|
CN114507284B
(zh)
*
|
2020-05-09 |
2023-05-26 |
华博生物医药技术（上海）有限公司 |
抗tigit的抗体、其制备方法和应用
|
|
CR20220611A
(es)
|
2020-06-02 |
2023-06-07 |
Arcus Biosciences Inc |
Anticuerpos anti-tigit
|
|
IL298946A
(en)
|
2020-06-18 |
2023-02-01 |
Genentech Inc |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
|
WO2021258337A1
(en)
*
|
2020-06-24 |
2021-12-30 |
Huahui Health Ltd. |
Human monoclonal antibodies against tigit for immune related diseases
|
|
CN111718415B
(zh)
*
|
2020-07-03 |
2021-02-23 |
上海洛启生物医药技术有限公司 |
一种抗tigit纳米抗体及其应用
|
|
TW202216778A
(zh)
|
2020-07-15 |
2022-05-01 |
美商安進公司 |
Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
|
|
US20230265187A1
(en)
*
|
2020-08-05 |
2023-08-24 |
Crystal Bioscience Inc. |
Anti-tigit antibody and methods of use thereof
|
|
AU2021357841A1
(en)
|
2020-10-08 |
2023-06-15 |
Affimed Gmbh |
Trispecific binders
|
|
WO2022112198A1
(en)
|
2020-11-24 |
2022-06-02 |
Worldwide Innovative Network |
Method to select the optimal immune checkpoint therapies
|
|
WO2022148781A1
(en)
|
2021-01-05 |
2022-07-14 |
Institut Curie |
Combination of mcoln activators and immune checkpoint inhibitors
|
|
EP4294948A1
(en)
|
2021-02-17 |
2023-12-27 |
iTeos Belgium SA |
Compounds, compositions and methods of treatment thereof
|
|
CA3213917A1
(en)
|
2021-04-09 |
2022-10-13 |
Nicolas Poirier |
New scaffold for bifunctional molecules with improved properties
|
|
WO2022214652A1
(en)
|
2021-04-09 |
2022-10-13 |
Ose Immunotherapeutics |
Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
|
|
TW202304965A
(zh)
|
2021-05-04 |
2023-02-01 |
美商艾吉納斯公司 |
抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法
|
|
JP2024527049A
(ja)
|
2021-07-28 |
2024-07-19 |
ジェネンテック， インコーポレイテッド |
がんを治療するための方法及び組成物
|
|
JP2024529381A
(ja)
|
2021-07-30 |
2024-08-06 |
アフィメド ゲーエムベーハー |
デュプレックスボディ
|
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
|
US20250179176A1
(en)
|
2022-05-02 |
2025-06-05 |
Arcus Biosciences, Inc. |
Anti-tigit antibodies and uses of the same
|
|
IL317449A
(en)
|
2022-06-07 |
2025-02-01 |
Genentech Inc |
Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
|
|
WO2024003360A1
(en)
|
2022-07-01 |
2024-01-04 |
Institut Curie |
Biomarkers and uses thereof for the treatment of neuroblastoma
|
|
JP2025525886A
(ja)
|
2022-08-02 |
2025-08-07 |
オーエスイー・イミュノセラピューティクス |
Ｃｄ２８に対する多機能性分子
|
|
EP4687990A1
(en)
|
2023-03-30 |
2026-02-11 |
Ose Immunotherapeutics |
Method of synthesis of targeted lipid nanoparticle and uses thereof
|
|
WO2024200823A1
(en)
|
2023-03-30 |
2024-10-03 |
Ose Immunotherapeutics |
Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
|
|
WO2025068461A1
(en)
|
2023-09-29 |
2025-04-03 |
Negio Therapeutics |
Guanfacine derivatives and their use in treating cancer
|
|
WO2025068452A1
(en)
|
2023-09-29 |
2025-04-03 |
Negio Therapeutics |
Guanfacine derivatives and their use in treating cancer
|
|
WO2025132831A1
(en)
|
2023-12-19 |
2025-06-26 |
Universite D'aix-Marseille |
N-heteroaryl derivatives and uses thereof for treating cancer
|
|
WO2025242836A1
(en)
|
2024-05-22 |
2025-11-27 |
Ose Immunotherapeutics |
Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
|
|
WO2025242835A1
(en)
|
2024-05-22 |
2025-11-27 |
Ose Immunotherapeutics |
Molecules comprising masking linkers and uses thereof for the treatment of cancer
|
|
WO2025255297A1
(en)
*
|
2024-06-05 |
2025-12-11 |
Agilent Technologies, Inc. |
Anti-human tigit antibodies for in vitro diagnostics
|
|
WO2025262250A1
(en)
|
2024-06-20 |
2025-12-26 |
Negio Therapeutics |
Guanfacine derivatives and their uses
|